Clinical and prognostic significance of T-regulatory cells and CD28 expression on T-lymphocytes in patients with immune thrombocytopenia

Cover Page

Cite item

Full Text

Abstract

Background. The leading role in the control of the immune response and peripheral tolerance is played by T-regulatory cells, as well as costimulatory molecules C28 on T-lymphocytes, which are necessary for effective activation. While T-regulatory cells in immune thrombocytopenia (IT) are actively studied in order to find an effective influence on their functions, publications on the study of costimulation processes in this disease are quite rare. Given the pronounced immunosuppressive effect of glucocorticosteroids (GCS) used in the treatment of patients with IT, it seems particularly relevant to study the role of T-regulatory cells and the expression features of costimulatory C28 molecules on T-lymphocytes to expand our understanding of the disease pathogenesis and justify new approaches to treating patients in real clinical practice.

Aim. To evaluate the clinical and prognostic significance of T-regulatory cells and C28 expression on peripheral blood T-lymphocytes in patients with newly diagnosed IT and resistant to GCS therapy.

Materials and methods. The content of T-regulatory cells and C28 expression features on peripheral blood T-lymphocytes were studied by flow cytometry in 18 patients with newly diagnosed IT and 19 patients resistant to GCS therapy. Thirty healthy individuals were examined as a control group.

Results. A significant (p ˂ 0.05) decrease in the content of classical T-regulatory cells (C4+C25+hiC127–) was revealed both in patients with newly diagnosed IT and in those resistant to GCS, while no significant differences were found in C8+C28– peripheral T-regulatory cells level in patients with IT of both groups compared to healthy individuals. In patients with IT of both groups, a significant increase in the proportion of T-helper (p < 05; p ˂ 01, respectively) and cytotoxic C8+ (p ˂ 0.05; p ˂ 0.01, respectively) T-lymphocytes expressing C28 was found compared to normal values. The level of T-helper lymphocytes (C4+C28–) was 2 times higher in the group of patients with resistance to GCS compared to newly diagnosed IT patients, and 3.5 times higher compared to healthy individuals.

Conclusion. T-regulatory cells and expression of C28 costimulatory molecules play an important role in the immunopathogenesis of IT. A significant increase in the content of the C4+C28null lymphocyte population (C4+C28–) in the peripheral blood of IT patients can be a prognostic criterion for GCS resistance, which may require a revision of the treatment strategy.

About the authors

Yu. Yu. Chuksina

M.F. Vladimirskiy Moscow Regional Research Clinical Institute;
A.S. Loginov Moscow Clinical Scientific Center, Moscow Healthcare Department

Author for correspondence.
Email: tchuxina2009@yandex.ru
ORCID iD: 0000-0002-4393-1759

Yulia Yuryevna Chuksina,

61/2 Shchepkina St., Moscow 129110;

Build. 1, 1 Novogireevskaya St., Moscow 111123

Russian Federation

S. G. Zakharov

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

ORCID iD: 0000-0003-2847-4374

61/2 Shchepkina St., Moscow 129110

Russian Federation

T. A. Mitina

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

ORCID iD: 0000-0001-7493-0030

61/2 Shchepkina St., Moscow 129110

Russian Federation

A. N. Khmelevskaya

A.S. Loginov Moscow Clinical Scientific Center, Moscow Healthcare Department

ORCID iD: 0009-0005-6618-0707

Build. 1, 1 Novogireevskaya St., Moscow 111123

Russian Federation

References

  1. Clinical recommendations. Idiopathic thrombocytopenic purpura (ITP) in adults. 2021. Available at: https://cr.minzdrav.gov.ru/schema/150_2 (accessed 04.02.2024). (In Russ.).
  2. Kovaleva L.G., Safonova T.I. Idiopathic thrombocytopenic purpura (ITP) of adults. Primary immune thrombocytopenia (ITP) in adults. Werlhof’s disease. Available at: https://rusneb.ru/catalog/000200_000018_RU_NLR_BIBL_A_010699665/ (accessed 04.02.2024). (In Russ.).
  3. Provan D., Arnold D.M., Bussel J.B. et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 2019;3(22):3780–817. doi: 10.1182/bloodadvances2019000812
  4. Rodeghiero F., Stasi R., Gernsheimer T. et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from international working group. Blood 2009;113(11):2386–93. doi: 10.1182/blood200807162503
  5. Michel M. Immune thrombocytopenia nomenclature, consensus reports, and guidelines: what are the consequences for daily practice and clinical research? Semin Hematol 2013;50(Suppl 1):550–4. doi: 10.1053/J.Seminhematol.2013.03.008
  6. Grozovsky R., Begonja A.J., Liu K. et al. The Ashwell–Morell receptor regulates hepatic thrombopoietin production via JAK2STAT3 signaling. Nat Med 2015;21(1):47–54. doi: 10.1038/nm.3770
  7. Zhao C., Li X., Zhang F. et al. Increased cytotoxic Tlymphocyte mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies. Haematologica 2008;93(9):1428–30. doi: 10.3324/haematol.12889
  8. Cines D.B., Cuker A., Semple J.W. Pathogenesis of immune thrombocytopenia. Presse Med 2014;43(4 Pt 2):e49–59. doi: 10.1016/j.lpm.2014.01.010
  9. Sakaguchi S., Sakaguchi N., Shimizu J. et al. Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001;182:18–32. doi: 10.1034/j.1600065x.2001.1820102.x
  10. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008;133(5):775–87. doi: 10.1016/j.cell.2008.05.009
  11. Freydlin I.S. Tegulatory Tcells: origin and function. Meditsinskaya immunologiya = Medical Immunology 2005;7(4):347–54. (In Russ.). doi: 10.1016/j.cell.2008.05.009
  12. Zheng S.G., Wang J., Wang P. et al. IL2 is essential for TGFbeta to convert naive CD4+CD25− cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol 2007;178(4):2018–27. doi: 10.4049/jimmunol.178.4.2018
  13. Shevyrev D., Tereshchenko V. Treg heterogeneity, function, and homeostasis. Front Immunol 2020;10:3100. doi: 10.3389/fimmu.2019.03100
  14. Kadagidze Z.G., Chertkova A.I. Immunity and cancer. Prakticheskaya onokologiya = Practical Oncology 2016;17(2):62–73. (In Russ.).
  15. Huff W.X., Kwon J.H., Henriquez M. et al. The evolving role of CD8+CD28− immunosenescent T cells in cancer immunology. Int J Mol Sci 2019;20(11):2810. doi: 10.3390/ijms20112810
  16. Hui E., Cheung J., Zhu J. et al. T cell costimulatory receptor CD28 is a primary target for PD1 mediated inhibition. Science 2017;355(6332):1428–33. doi: 10.1126/science.aaf1292
  17. BrunnerWeinzierl M.C., Hoff H., Burmester G.R. Multiple function for CD28 and cytotoxic Tlymphocyte antigen4 during different phases of Tcell responses: implications for arthritis and autoimmune diseases. Arthritis Res Ther 2004;6(2):45–54. doi: 10.1186/ar1158
  18. Zakharov S.G., Mitina T.A., Zakharova A.V. et al. Glucocorticosteroidinduced complications in patients with idiopathic thrombocytopenic purpura. Onkogematologiya = Oncohematology 2023;18(4):233–43. (In Russ.). doi: 10.17650/1818¬8346¬2023¬18¬4¬233¬243
  19. Melikyan A.L., Pustovaya E.I., Kalinina M.V. et al. Epidemiological characteristics of primary immune thrombocytopenia in adult population of the Russian Federation. Klinicheskaya onkogematologiya = Clinical Oncohematology 2017;4(10):558–9. (In Russ.).
  20. Melikyan A.L., Pustovaya E.I., Egorova E.K. et al. Differential diagnosis of thrombocytopenes. Onkogematologiya = Oncohematology 2017;12(1):78–87. (In Russ.). doi: 10.17650/1818834620171217887
  21. Zufferey A., Kapur R., Semple J.W. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J Clin Med 2017;6(2):16. doi: 10.3390/jcm6020016
  22. Li L., Zhao Y., Tong X. et al. The predictive value of regulatory T cells on glucocorticoid sensitivity in patients with immune thrombocytopenia: a multicentre, prospective clinical study. Br J Haematol 2021;193(3):619–27. doi: 10.1111/bjh.17368
  23. Yarilin A.A. Adaptive immunity. In: Immunology. Moscow: GEOTARMedia, 2010. Pp. 231–512. (In Russ.).
  24. Thewissen M., Somers V., Hellings N. et al. CD4+CD28null T cells in autoimmune disease: pathogenic features and decreased susceptibility to immunoregulation. J Immunol 2007;179(10): 6514–23. doi: 10.4049/jimmunol.179.10.6514
  25. Bano A., Pera A., Almoukayed A. et al. CD28nullCD4 Tcell expansions in autoimmune disease suggest a link with cytomegalovirus infection. F1000Res 2019;8:F1000 Faculty Rev327. doi: 10.12688/f1000research.17119.1
  26. Pera A., Caserta S., Albanese F. et al. CD28null proatherogenic CD4 Tcells explain the link between CMV infection and an increased risk of cardiovascular death. Theranostics 2018;8(16):4509–19. doi: 10.7150/thno.27428
  27. Shabir S., Smith H., Kaul B. et al. Cytomegalovirusassociated CD4+CD28null cells in NKG2Ddependent glomerular endothelial injury and kidney allograft dysfunction. Am J Transplant 2016;16(4):1113–28. doi: 10.1111/ajt.13614
  28. EscarraSenmarti M., BuenoTopete M.R., JaveSuarez L.F. et al. Loss of CD28 within CD4+ T cell subsets from cervical cancer patients is accompanied by the acquisition of intracellular perforin, and is further enhanced by NKG2D expression. Immunol Lett 2017;182:30–8. doi: 10.1016/j.imlet.2017.01.006
  29. Guan Y., Cao M., Wu X. et al. CD28null T cells in aging and diseases: from biology to assessment and intervention. Int Immunopharmacol 2024;131:111807. doi: 10.1016/j.intimp.2024.111807

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36928 от  21.07.2009.